initial public offerings (IPOs) trading on American exchanges

Friday, May 22, 2020

Adaptimmune Therapeutics (ADAP) : positive data on experimental cell therapy

  • The company said that trials of its SPEAR T-cell therapy showed a 50% response rate in patients with synovial sarcoma. The company also reported confirmed responses in lung cancer patients, and had previously reported confirmed responses in head and neck cancer patients. 


Adaptimmune Therapeutics presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology Annual Meeting

  • New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy.
  • Durability and efficacy data presented at ASCO support potential for SPEARHEAD-1 as a registrational trial for sarcoma - commercial launch planned in the US in 2022.
  • Phase 2 trial combining ADP-A2M4 with pembrolizumab in head and neck cancer (SPEARHEAD-2) will be the first time a SPEAR T-cell therapy is used in sequence with first line systemic therapy.
  • The company also announced new responses in the SURPASS trial, confirming the potential for SPEAR T-cell therapies targeting MAGE-A4 to treat a broad range of cancers in addition to sarcoma. These data further support the rationale for two new Phase 2 trials -- SPEARHEAD-2 in head and neck cancer, which will begin later this year, and a second trial in esophagogastric junction (EGJ) cancer planned for 1H 2021.
  • The SURPASS trial (a Phase 1 trial with ADP-A2M4CD8) will focus on lung, EGJ, head and neck, and bladder cancers.
  • Confirmed complete response in a patient with liver cancer in the Phase 1 ADP-A2AFP trial (reported as partial response in January).
  • No comments:

    Post a Comment